Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins clinical trial pipeline

12 trials changed in the last 30 days: 0 stopped, 5 with notable changes, 7 with minor changes only.

1. Notable

   Subventricular Zone (SVZ) and Temozolomide in Glioblastoma…Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme

   Primary completion pushed from Aug 2026 to Apr 2027

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2· NCT02177578· Registry history of NCT02177578 on ClinicalTrials.gov (opens the registry)

   Oct 20, 2026

2. Notable

   Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient…Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

   Primary and study completion pushed from Oct 2026 to Oct 2027

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2· NCT03607890· Registry history of NCT03607890 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

3. Notable

   Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before…Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

   Primary completion pushed from Sep 2026 to Sep 2027

   Also in this update: Study completion pushed from Mar 2027 to Mar 2028

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Early Phase 1· NCT06398457· Registry history of NCT06398457 on ClinicalTrials.gov (opens the registry)

   Sep 24, 2026

4. Notable

   PSMA-High · EBRT/ PSMA617/ ADT vs. EBRT/ ADT

   Recruitment opened

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2· NCT07550517· Registry history of NCT07550517 on ClinicalTrials.gov (opens the registry)

   Sep 22, 2026

5. Notable

   DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With…DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab · Advanced Stage Fibrolamellar Carcinoma (FLC)

   Recruitment opened

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1· NCT07430202· Registry history of NCT07430202 on ClinicalTrials.gov (opens the registry)

   Oct 5, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.